Tari Ao Whānui

I te 22 o Hānuere, 2025, i whakaputaina e te "Nature Medicine" ngā hua o te cadonilimab, he antibody bispecific PD-1/CTLA-4 i whakawhanakehia motuhaketia e Akeso, me te oxaliplatin me te capecitabine, hei rongoā tuatahi mō te mate puku, mate gastroesophageal rānei kua horapa, kua horapa rānei, kāore e taea te tango...Pānuihia atu»

I te 8 o Hānuere, 2025, kua whakaaetia e te Whakahaere Hua Hauora ā-Motu o Haina (NMPA) te PADCEVTM (enfortumab vedotin) me te KEYTRUDA (pembrolizumab) mō ngā tūroro pakeke e pangia ana e te mate pukupuku urothelial ā-rohe kua whanake haere, kua horapa rānei (la/mUC). Ko te whakaaetanga a te NMPA mō te enfortumab vedotin i roto i te...Pānuihia atu»

I te 17 o Pēpuere, 2025, i panuitia e Innovent Biologics kua whiwhi tana pūmua whakakotahitanga paturopi bispecific PD-1/IL-2α-bias tuatahi o te karaehe, arā, ko IBI363, i tana Tohu Ara Tere tuarua (FTD) mai i te US Food and Drug Administration (FDA). E pā ana tēnei tohu ki te maimoatanga o ngā pūtau kāore e taea te tango, ...Pānuihia atu»

I te 16 o Hānuere, 2025, i panuitia e IMPACT kua whiwhi a Senaparib Capsules (派舒宁®) i te whakaaetanga hokohoko i Haina mai i te National Medical Products Administration (NMPA) hei monotherapy mō te maimoatanga pupuri i ngā tūroro pakeke me ngā mate epithelial matatau (FIGO Stages III me IV) ov-grade teitei...Pānuihia atu»

I te 7 o Pēpuere, 2025, i whakapuakina e Sichuan Kelun-Biotech Biopharmaceutical te whakaaetanga o tana Werohanga Cetuximab N01 e te National Medical Products Administration mō te rongoā i te mate pukupuku colorectal metastatic (mCRC) i Haina. Ko te whakaaetanga i ahu mai i tētahi rangahau haumanu wāhanga III nui e whakaatu ana...Pānuihia atu»

I te 10 o Pēpuere, 2025, ka panuitia e CARsgen Therapeutics kua tutuki i te tangata tuatahi i rongoatia ki te rongoā BCMA CAR-T allogeneic i whakawhanakehia i runga i te tūāpapa THANK-u Plus™ te urupare tino pakari (sCR) me te iti o te mate toenga (MRD) i te aromatawai o te Rā-28. I whakawhanakehia i roto i te whare...Pānuihia atu»

I te 29 o Hānuere, 2025, i whakaputahia e tētahi rōpū rangahau Hainamana tētahi tuhinga ko "Neoadjuvant pyrotinib and trastuzumab in HER2 positive breast cancer with no early response (NeoPaTHer): effectiveness, safety, and biomarker analysis of a prospective, multicenter, response adapted study" i roto i te...Pānuihia atu»

I te 26 o Hānuere, 2025, i panuitia e te Pokapū Arotake Rongoā (CDE) o te Whakahaere Hua Hauora ā-Motu o Haina ko te werohanga LM-108 te mea hei whakauru ki te rongoā hou mō ngā pukupuku totoka matatau me te kore pumau o te microsatellite (MSI-H) me ngā hapa whakatika taurite kore (dMMR)...Pānuihia atu»

I te 20 o Hānuere, i whakaaetia e te National Medical Products Administration (NMPA) te rongoā whakakotahitanga hou o te tagitanlimab (KL-A167) o te cisplatin me te gemcitabine hei rongoā tuatahi mō ngā tūroro mate pukupuku nasopharyngeal (NPC) e hokihoki mai ana, e horapa mai ana rānei. ...Pānuihia atu»

I te 16 o Hānuere, 2025, kua whakaaetia e te Whakahaere Hua Hauora ā-Motu o Haina (NMPA) te Tono Rongoā Hou (NDA) o te limertinib mō te rongoā i ngā tūroro pakeke e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) kua horapa ki te rohe, kua horapa rānei. Mō Limertinib Limertinib ...Pānuihia atu»

I te 8 o Hānuere, i whakawhiwhia e te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) te Breakthrough Therapy Designation (BTD) mō te IBI343, he TOPO1i anti-CLDN18.2 ADC pai rawa atu pea i roto i tana karaehe, hei monotherapy mō te rongoā o te CLDN18.2-positive advanced pancr...Pānuihia atu»

I te 8 o Hānuere, 2025, i whakawhiwhia a 9MW2821 ki te Tohu Whakamanatanga Whakaora Pakari (BTD) e te Center for Drug Evaluation (CDE) o te National Medical Products Administration (NMPA) i Haina. Ka hoatu te 9MW2821 me te toripalimab, he paturopi monoclonal anti-PD-1, mō ngā mate kāore anō kia rongoatia, kāore anō kia tangohia...Pānuihia atu»